{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T01:10:14Z","timestamp":1771377014564,"version":"3.50.1"},"reference-count":32,"publisher":"BMJ","issue":"10","license":[{"start":{"date-parts":[[2021,10,24]],"date-time":"2021-10-24T00:00:00Z","timestamp":1635033600000},"content-version":"unspecified","delay-in-days":23,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2021,9,24]]},"published-print":{"date-parts":[[2021,10]]},"abstract":"<jats:p>The role and use of independent data monitoring committees (IDMCs) has evolved over the past decades. The Food and Drug Administration and European Medicines Agency have issued guidelines on the role and functioning of such committees. In general, data monitoring committees are recommended for large, often randomised clinical trials involving life-threatening diseases, studies performed in vulnerable populations or where the experimental intervention can potentially harm the trial participant. Such committees play an important role in trials evaluating treatments with the potential to prolong life or reduce the risk of major adverse health outcomes.<\/jats:p>\n                  <jats:p>Typically, oncology clinical trials fall within these recommendations, as they are often large, randomised, multicentric protocols aiming at improving survival outcomes by exploring the use of study treatments that may be associated with a significant risk of serious, even life-threatening adverse events. IDMCs are required for National Cancer Institute phase III randomised trials, European Organisation for Research and Treatment of Cancer phase II\/III trials with formal interim analyses, early-stopping rules or adaptive studies. The primary role of an IDMC of ensuring the safety of study participants and maintaining clinical trial integrity is particularly important in oncology trials, due to the nature of the disease, the potential for treatment toxicity and for instilling confidence that the clinical trial data are reliable. A clear understanding by IDMC members of the natural course of the disease, treatment landscape, importance and relevance of certain adverse events in trial participants, clinical trial methodology in general and stopping rules for oncology trials in particular, is crucial for the functioning of an IDMC.<\/jats:p>\n                  <jats:p>It is recommended that IDMC members should be experienced trialists, have a track record of strong clinical, statistical and\/or methodological expertise and the required level of independence, as they play a highly important role in the protection of study participants, and in commercially and strategically important go\/no decisions. Ideally, IDMC members should have relevant experience or have some training, mentorship or guidelines.<\/jats:p>","DOI":"10.1136\/bmjopen-2020-047294","type":"journal-article","created":{"date-parts":[[2021,10,25]],"date-time":"2021-10-25T14:45:10Z","timestamp":1635173110000},"page":"e047294","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":12,"title":["Importance and role of independent data monitoring committees (IDMCs) in oncology clinical trials"],"prefix":"10.1136","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5980-030X","authenticated-orcid":false,"given":"P","family":"Sch\u00f6ffski","sequence":"first","affiliation":[{"name":"Department of General Medical Oncology, University Hospitals Leuven, KU Leuven, Leuven Cancer Institute, Leuven, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2021,10,25]]},"reference":[{"key":"2025121605461582000_11.10.e047294.1","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.urolonc.2014.12.013","article-title":"Independent data monitoring committees: an update and overview","volume":"33","author":"Sartor","year":"2015","journal-title":"Urol Oncol"},{"key":"2025121605461582000_11.10.e047294.2","unstructured":"National Institutes of Health (NIH) guide. volume 8 number 8, 1979. Available: file:\/\/\/C:\/Users\/Admin\/Documents\/My%20documents\/From%20PC%203%20Sept%202018\/2020%20-%202019%20Schoffski%20-%20data%20monitoring%20article\/From%20internet%20-%20marked%20up\/NIH%20guide.%20Volume%208%20number%208,%20June%205,%201979.pdf [Accessed 27 Feb 2020]."},{"key":"2025121605461582000_11.10.e047294.3","unstructured":"U.S. Department of Health and Human Services. Food and Drug Administration . Guidance for clinical trial sponsors. Establishment and operation of clinical trial data monitoring committees. March 2006. omb control No. 0910-0581 (expiration date: 10\/31\/2021). Available: https:\/\/www.fda.gov\/media\/75398\/download [Accessed 27 Feb 2020]."},{"key":"2025121605461582000_11.10.e047294.4","unstructured":"CTSA Collaborative DSMB Workgroup . DSMB training manual. Medford, MA: Tufts Digital Library, 2018. https:\/\/www.tuftsctsi.org\/research-services\/regulatory\/data-and-safety-monitoring-board-training-manual-for-investigator-initiated-studies\/"},{"key":"2025121605461582000_11.10.e047294.5","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1177\/1740774516688915","article-title":"Data monitoring committees: promoting best practices to address emerging challenges","volume":"14","author":"Fleming","year":"2017","journal-title":"Clin Trials"},{"key":"2025121605461582000_11.10.e047294.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2014.05.003"},{"key":"2025121605461582000_11.10.e047294.7","unstructured":"Sirbu C , Lucas BD , Broce M , et al . Data & Safety Monitoring Boards in Industry-Sponsored Clinical Trials. J Clin Res Best Pract 2008;4 http:\/\/citeseerx.ist.psu.edu\/viewdoc\/download?doi=10.1.1.536.7276&rep=rep1&type=pd"},{"key":"2025121605461582000_11.10.e047294.8","unstructured":"World Health Organization (WHO) . UNICEF \/ UNDP \/ WORLD BANK \/ WHO special programme for research and training in tropical diseases (TDR). Operational guidelines for the establishment and functioning of data and safety monitoring boards. 2005, TDR\/GEN\/Guidelines\/05.1. Available: https:\/\/www.who.int\/tdr\/publications\/tdr-research-publications\/operational-guidelines\/en\/ [Accessed 03 Mar 2020]."},{"key":"2025121605461582000_11.10.e047294.9","unstructured":"European Medicines Agency (EMEA) . Guideline on data monitoring committees. Doc. Ref. EMEA\/CHMP\/EWP\/5872\/03 Corr, 2005. Available: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-data-monitoring-committees_en.pdf [Accessed 03 Mar 2020]."},{"key":"2025121605461582000_11.10.e047294.10","unstructured":"Collette L . European Organisation for Research and Treatment of Cancer (EORTC). Independent data monitoring committees for EORTC studies. POL004 version 3.0, 2016. Available: https:\/\/www.eortc.org\/app\/uploads\/2017\/03\/POL004-v-3-0.pdf [Accessed 09 Mar 2020]."},{"key":"2025121605461582000_11.10.e047294.11","doi-asserted-by":"publisher","DOI":"10.1191\/1740774504cn004rr"},{"key":"2025121605461582000_11.10.e047294.12","unstructured":"National Institutes of Health (NIH) . Further guidance on a data and safety monitoring for phase I and phase II trials. Notice: OD-00-038, 2000. Available: https:\/\/nccih.nih.gov\/node\/9221 [Accessed 10 Mar 2020]."},{"key":"2025121605461582000_11.10.e047294.13","first-page":"40","article-title":"On independent data monitoring committees in oncology clinical trials","volume":"3","author":"Wittes","year":"2014","journal-title":"Chin Clin Oncol"},{"key":"2025121605461582000_11.10.e047294.14","unstructured":"ICH Harmonised Tripartite Guideline: guideline for good clinical practice E6 (R1). International Conference on Harmonisation of technical requirements for registration of pharmaceuticals for human use, 1996. Available: https:\/\/www.gmp-compliance.org\/guidelines\/gmp-guideline\/ich-e6r2integrated-addendum-to-ich-e6r1-guideline-for-goodclinical-practice [Accessed 20 Apr 2020]."},{"key":"2025121605461582000_11.10.e047294.15","unstructured":"National Cancer Institute (NCI) . Policy of the National Cancer Institute for data and safety monitoring of clinical trials. Approved by the NCI Clinical and Translational Research Operations Committee (CTROC), 2014. Available: https:\/\/deainfo.nci.nih.gov\/grantspolicies\/datasafety.pdf [Accessed 10 Mar 2020]."},{"key":"2025121605461582000_11.10.e047294.16","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1177\/1740774516679665","article-title":"Understanding the functions and operations of data monitoring committees: survey and focus group findings","volume":"14","author":"Calis","year":"2017","journal-title":"Clin Trials"},{"key":"2025121605461582000_11.10.e047294.17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001234","article-title":"Protecting clinical trial participants and protecting data integrity: are we meeting the challenges?","volume":"9","author":"Ellenberg","year":"2012","journal-title":"PLoS Med"},{"key":"2025121605461582000_11.10.e047294.18","doi-asserted-by":"crossref","first-page":"605","DOI":"10.4155\/cli.13.47","article-title":"Data monitoring committees in adaptive clinical trials","volume":"3","author":"Lin","year":"2013","journal-title":"Clin Investig"},{"key":"2025121605461582000_11.10.e047294.19","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1056\/NEJMra1510066","article-title":"Data monitoring committees - expect the unexpected","volume":"375","author":"DeMets","year":"2016","journal-title":"N Engl J Med"},{"key":"2025121605461582000_11.10.e047294.20","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1002\/ejhf.761","article-title":"Independent academic data monitoring committees for clinical trials in cardiovascular and cardiometabolic diseases","volume":"19","author":"Filippatos","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2025121605461582000_11.10.e047294.21","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1186\/bcr1280","article-title":"Early stopping of clinical trials","volume":"7","author":"Cuzick","year":"2005","journal-title":"Breast Cancer Res"},{"key":"2025121605461582000_11.10.e047294.22","unstructured":"Collette L . European Organisation for Research and Treatment of Cancer (EORTC). Permanent Independent Data Monitoring Committee (IDMC) for EORTC studies. IDMC charter. Version 1.0, 2015. Available: https:\/\/www.eortc.org\/app\/uploads\/2017\/06\/IDMC-charter.pdf [Accessed 12 Mar 2020]."},{"key":"2025121605461582000_11.10.e047294.23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0201037","article-title":"\"You have to keep your nerve on a DMC.\" Challenges for data monitoring committees in neonatal intensive care trials: Qualitative accounts from the BRACELET Study","volume":"13","author":"Snowdon","year":"2018","journal-title":"PLoS One"},{"key":"2025121605461582000_11.10.e047294.24","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1177\/2168479013486996","article-title":"Views on emerging issues pertaining to data monitoring committees for adaptive trials","volume":"47","author":"Antonijevic","year":"2013","journal-title":"Ther Innov Regul Sci"},{"key":"2025121605461582000_11.10.e047294.25","unstructured":"Radiation Therapy Oncology Group (RTOG) . Phase III data monitoring committee, 2005. Available: https:\/\/www.rtog.org\/LinkClick.aspx?fileticket=R3fG2hYgdqE=&tabid=183 [Accessed 16 May 2020]."},{"key":"2025121605461582000_11.10.e047294.26","unstructured":"Australian Government National Health and Medical Research Council . Data safety monitoring boards (DSMBs), 2018. Available: https:\/\/www.australianclinicaltrials.gov.au\/sites\/default\/files\/content\/For%20researchers\/Data%20Safety%20Monitoring%20Boards_1.pdf [Accessed 16 May 2020]."},{"key":"2025121605461582000_11.10.e047294.27","unstructured":"Harvard Catalyst, The Clinical and Translation Science Center . Data and safety monitoring guidance, 2018. Available: https:\/\/catalyst.harvard.edu\/pdf\/regulatory\/DSMB-P_Guidance.pdf [Accessed 26 May 2020]."},{"key":"2025121605461582000_11.10.e047294.28","doi-asserted-by":"publisher","DOI":"10.1191\/1740774506cn149oa"},{"key":"2025121605461582000_11.10.e047294.29","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)17965-3"},{"key":"2025121605461582000_11.10.e047294.30","doi-asserted-by":"crossref","first-page":"viii47","DOI":"10.1093\/annonc\/mds263","article-title":"Evolution of end points for cancer immunotherapy trials","volume":"23 Suppl 8","author":"Hoos","year":"2012","journal-title":"Ann Oncol"},{"key":"2025121605461582000_11.10.e047294.31","unstructured":"Southwest Oncology Group (SWOG) . Policy memorandum no 21, data and safety monitoring policy, 2013. Available: https:\/\/www.swog.org\/sites\/default\/files\/docs\/2017-10\/Policy21.pdf [Accessed 30 Aug 2021]."},{"key":"2025121605461582000_11.10.e047294.32","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1177\/1740774518772841","article-title":"The independent statistician model: how well is it working?","volume":"15","author":"DeMets","year":"2018","journal-title":"Clin Trials"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2020-047294","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T13:46:29Z","timestamp":1765892789000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2020-047294"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":32,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2021,10,25]]},"published-print":{"date-parts":[[2021,10]]}},"alternative-id":["10.1136\/bmjopen-2020-047294"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2020-047294","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10]]}}}